Gout Opportunity Analysis and Forecast to 2018, New Report Launched

Novel Therapies to Boost Gout Disease Treatment Market, but Physician Education Needs to Be Improved, says Publisher

Thanks to the introduction of novel therapies in the near future, the gout disease treatment market value will increase from $989 million in 2013 to $2.28 billion by 2018, at a significant Compound Annual Growth Rate (CAGR) of 18.2%, forecasts research and consulting firm by Publisher.

The company’s latest report* states that out of the six major markets (6MM: the US, France, Germany, Italy, Spain and the UK), the US accounted for 90% of the 2013 gout treatment sales. This was due to the wide use of Colcrys therapy, which is not generically available in the US, as well as the high prevalence of gout in the country.

The five European countries (5EU) are now experiencing a dramatic increase in gout prevalence, which is 2.3 times faster than in the US. By the end of the forecast period, Publisher expects the 5EU to have a market share of 12.5%.

According to Analyst covering Cardiovascular & Metabolic Disorders, says: “With the recent approval of the powerful anti-inflammatory therapy Ilaris, and the market entry of two novel urate-lowering therapies, lesinurad and ulodesine, physicians will have more options available to tackle difficult-to-treat gout.”

However, Gburcik says that despite advances in gout disease treatment, physician education remains the greatest unmet need in the gout therapeutics market.

The analyst continues: “The standard treatments are effective in most gout patients, therefore making gout a potentially curable disease. However, there is a growing number of patients for whom the standard therapies are inappropriate.

“Since most physicians still do not take gout seriously enough, they are passing on this attitude to their patients, who are consequently unaware of the importance of keeping their urate levels down and are not sticking to the appropriate therapy. This in turn is leading to an increase in the difficult-to-treat patient pool,” Gburcik concludes.

"OpportunityAnalyzer: Gout - Opportunity Analysis and Forecast to 2018" report provides an overview of gout disease, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. It also provides annualized gout therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 to 2018.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by Publisher’s team of industry experts.

Browse this report:  http://mrr.cm/Zgn

Find all Pharma and Healthcare reports at: http://www.marketresearchreports.com/pharma-healthcare

Wearable Devices in Healthcare 2014 – 2020, New Report Launched

The wearable devices industry has grown dramatically during the last four years. The market value is currently relatively small for wearable devices but certain segments are expected to grow rapidly. Wearables are already making great in-roads in the fitness market. The overall healthcare market is expected to grow rapidly for wearables with some very specific scenarios and applications expected to excel in particular within the medical area.

In this report evaluates the current and anticipated wearable devices for the healthcare industry. The report addresses current wearables performance, what wearable devices should be used by healthcare professionals, why and in what circumstances. The report will also provide a full market analysis on the wearable devices in healthcare from 2015 to 2020.

Target Audience:

• Healthcare professionals
• Augmented reality companies
• Wireless device manufacturers
• Wireless infrastructure providers
• Consumer electronics companies
• Wearable technology developers
• Embedded computing companies
• Regulatory bodies and governments
• Wireless service providers of all types

Report Benefits:

• Market forecast for wearable tech in healthcare
• Understand the wearable technology marketplace
• Understand supporting technologies for wearables
• Recognize opportunities for wearable tech in healthcare
• Identify wearable technology vendor strategies and offerings

Spanning Over 96 pages and 31 Figures “Wearable Devices in Healthcare 2014 – 2020” report Provide Introduction, Wearable Devices Technologies Overview, E-Textile and Healthcare, Healthcare Related Sports Applications, Vendor Analysis, Internet of Things and Healthcare, Industry Developments and Direction, Market Forecasts 2015 - 2020.

Know more about this report at: http://mrr.cm/ZYk

Find other Pharma and Healthcare Technology Reports at : http://www.marketresearchreports.com/pharma-healthcare-technology

United States Cardiovascular Prosthetic Devices Market Outlook to 2020, New Report Launched

"United States Cardiovascular Prosthetic Devices Market Outlook to 2020", provides key market data on the United States Cardiovascular Prosthetic Devices market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market categories - Cardiac Valve Repairs and Septal Occluders.

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Cardiovascular Prosthetic Devices market wherever available.

The data in the report is derived from dynamic market forecast models. Publisher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

• Market size for Cardiovascular Prosthetic Devices categories - Cardiac Valve Repairs and Septal Occluders.
• Annualized market revenue (USD million), volume (units) and average selling price ($) data for the market categories. Data is provided from 2005 to 2012 and forecast to 2020.
• 2012 company shares and distribution shares data for the market category.
• Global corporate-level profiles of key companies operating within the United States Cardiovascular Prosthetic Devices market.
• Key players covered include Medtronic, Inc., Edwards Lifesciences Corporation, St. Jude Medical, Inc. and Sorin Group.

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth in the future.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the market.
• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.

Spanning over 49 pages, 17 tables, 12 figures, “United States Cardiovascular Prosthetic Devices Market Outlook to 2020” report covering the Cardiovascular Prosthetic Devices Market, United States, Overview of Key Companies in United States, Cardiovascular Prosthetic Devices Market, ardiovascular Prosthetic Devices Market Pipeline Products, Financial Deals Landscape, Recent Developments, Appendix. The report covered 5 companies - St. Jude Medical, Inc., Edwards Lifesciences Corporation, Medtronic, Inc., W. L. Gore & Associates, Inc., Sorin S.p.A.

Browse this report: http://mrr.cm/Zf8

United States Cardiovascular Monitoring and Diagnostic Devices Market Outlook to 2020, New Report Launched

"United States Cardiovascular Monitoring and Diagnostic Devices Market Outlook to 2020", provides key market data on the United States Cardiovascular Monitoring and Diagnostic Devices market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market categories - Cardiopulmonary Stress Testing Systems, ECG Data Management Systems, ECG Monitoring Equipment, ECG Stress Testing Systems, Event Monitoring Systems and Holter Monitoring Systems.

The report also provides company shares and distribution shares data for the market category, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Cardiovascular Monitoring and Diagnostic Devices market wherever available.

The data in the report is derived from dynamic market forecast models. Publisher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

• Market size for Cardiovascular Monitoring and Diagnostic Devices categories - Cardiopulmonary Stress Testing Systems, ECG Data Management Systems, ECG Monitoring Equipment, ECG Stress Testing Systems, Event Monitoring Systems and Holter Monitoring Systems.
• Annualized market revenue (USD million), volume (units) and average selling price ($) data for the market categories. Data is provided from 2005 to 2012 and forecast to 2020.
• 2012 company shares and distribution shares data for the market category.
• Global corporate-level profiles of key companies operating within the United States Cardiovascular Monitoring and Diagnostic Devices market.
• Key players covered include GE Healthcare, Philips Healthcare, Welch Allyn Inc., OSI Systems, Inc., CareFusion Corporation, Cardiac Science Corporation, Schiller AG and Card Guard Scientific Survival, Ltd.

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth in the future.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the market.
• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.

Spanning over 149 pages, 49 tables, 8 figures, “United States Cardiovascular Monitoring and Diagnostic Devices Market Outlook to 2020” report covering the Cardiovascular Monitoring and Diagnostic Devices Market, United States, Overview of Key Companies in United States, Cardiovascular Monitoring and Diagnostic Devices Market, Cardiovascular Monitoring and Diagnostic Devices Market Pipeline Products, Financial Deals Landscape, Recent Developments, Appendix. The report covered 10 companies - GE Healthcare, Philips Healthcare, CareFusion Corporation, Welch Allyn Inc., OSI Systems, Inc., Opto Circuits India Limited ,Schiller AG, Mortara Instrument, Inc., Nihon Kohden Corporation, Fukuda Denshi Co., Ltd.

Browse this report: http://mrr.cm/Zf7

Find other Reports on  United States Market at: 

http://www.marketresearchreports.com/countries/usa 

United States Prosthetic Heart Valves Market Outlook to 2020, New Report Launched

"United States Prosthetic Heart Valves Market Outlook to 2020", provides key market data on the United States Prosthetic Heart Valves market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market categories - Mechanical Heart Valves, Tissue Heart Valves and Transcatheter Heart Valves.

The report also provides company shares and distribution shares data for the market category, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Prosthetic Heart Valves market wherever available.

The data in the report is derived from dynamic market forecast models. Publisher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

• Market size for Prosthetic Heart Valves categories - Mechanical Heart Valves, Tissue Heart Valves and Transcatheter Heart Valves.
• Annualized market revenues (USD million), volume (units) and average selling price ($) data for each of the market categories. Data is provided from 2005 to 2012 and forecast to 2020.
• 2012 company shares and distribution shares data for the market category.
• Global corporate-level profiles of key companies operating within the United States Prosthetic Heart Valves market.
• Key players covered include Edwards Lifesciences Corporation, Medtronic, Inc., St. Jude Medical, Inc., Sorin Group and CryoLife, Inc.

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth in the future.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the market.
• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.

Spanning over 130 pages, 31 tables, 16 figures, “United States Prosthetic Heart Valves Market Outlook to 2020” report covering the Prosthetic Heart Valves Market, United States, Overview of Key Companies in United States, Prosthetic Heart Valves Market, Prosthetic Heart Valves Market Pipeline Products, Financial Deals Landscape, Recent Developments, Appendix. The report covered 4 companies - Edwards Lifesciences Corporation, Medtronic, Inc., St. Jude Medical, Inc., Sorin S.p.A.

Browse this report: http://mrr.cm/Zf6

United States Cardiac Assist Devices Market Outlook to 2020, New Report Launched

"United States Cardiac Assist Devices Market Outlook to 2020", provides key market data on the United States Cardiac Assist Devices market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market categories - Intra-Aortic Balloon Pumps, Total Artificial Heart and Ventricular Assist Devices.

The report also provides company shares and distribution shares data for the market category, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Cardiac Assist Devices market wherever available.

The data in the report is derived from dynamic market forecast models. Publisher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

• Market size for Cardiac Assist Devices categories - Intra-Aortic Balloon Pumps, Total Artificial Heart and Ventricular Assist Devices.
• Annualized market revenue (USD million), volume (units) and average selling price ($) data for the market categories. Data is provided from 2005 to 2012 and forecast to 2020.
• 2012 company shares and distribution shares data for the market category.
• Global corporate-level profiles of key companies operating within the United States Cardiac Assist Devices market.
• Key players covered include Thoratec Corporation, MAQUET GmbH & Co. KG, Teleflex Incorporated, ABIOMED, Inc. and HeartWare International, Inc.

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth in the future.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the market.
• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.

Spanning over 82 pages, 26 tables, 16 figures, “United States Cardiac Assist Devices Market Outlook to 2020” report covering the Cardiac Assist Devices Market, United States, Overview of Key Companies in United States, Cardiac Assist Devices Market, Cardiac Assist Devices Market Pipeline Products, Financial Deals Landscape, Recent Developments, Appendix. The report covered 7 companies - Thoratec Corporation, Maquet Holding B.V. & Co. KG., HeartWare International, Inc., Teleflex Incorporated, SynCardia Systems, Inc., Berlin Heart GmbH, Abiomed, Inc.

Browse this report: http://mrr.cm/Zfn

United States Cardiovascular Surgery Market Outlook to 2020, New Report Launched

"United States Cardiovascular Surgery Market Outlook to 2020", provides key market data on the United States Cardiovascular Surgery Market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market categories - Beating Heart Surgery Systems, Cardiac Ablation Devices, Cardiopulmonary Bypass Equipment and Perfusion Disposables.

The report also provides company shares and distribution shares data for the market category, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Cardiovascular Surgery Market wherever available.

The data in the report is derived from dynamic market forecast models. Publisher uses epidemiology and capital equipment-based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Capital equipment-based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

• Market size for Cardiovascular Surgery Devices categories - Beating Heart Surgery Systems, Cardiac Ablation Devices, Cardiopulmonary Bypass Equipment and Perfusion Disposables
• Annualized market revenue (USD million), volume (units) and average selling price ($) data for the market categories. Data is provided from 2005 to 2012 and forecast to 2020.
• 2012 company shares and distribution shares data for the market category.
• Global corporate-level profiles of key companies operating within the United States Cardiovascular Surgery Market.
• Key players covered include Medtronic, Inc., MAQUET GmbH & Co. KG, Sorin Group and Terumo Corporation.

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth in the future.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the market.
• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.

Spanning over 144 pages, 36 tables, 16 figures, “United States Cardiovascular Surgery Market Outlook to 2020” report covering the Cardiovascular Surgery Market, United States, Overview of Key Companies in United States, Cardiovascular Surgery Market, Cardiovascular Surgery Market Pipeline Products, Financial Deals Landscape, Recent Developments, Appendix. The report covered 4 companies - Medtronic, Inc., Maquet Holding B.V. & Co. KG., Sorin S.p.A., Terumo Corporation

Browse this report: http://mrr.cm/ZfB

Multiple Sclerosis - Epidemiology Forecast to 2023, New Report Launched

Multiple Sclerosis: India and China’s Prevalent Cases to Witness Highest Growth by 2023, says Publisher. The number of multiple sclerosis (MS) prevalent cases across the ten major markets (10MM) will increase from 904,908 in 2013 to 940,413 by 2023, at an Annual Growth Rate (AGR) of 0.39%, says research and consulting firm Publisher.

The company’s latest report* states that among the 10MM (the US, Canada, France, Germany, Italy, Spain, the UK, Japan, China and India), India will have the highest increase in prevalent cases, with an AGR of almost 2%, followed by Spain and China, with AGRs of 1.05% and 0.93%, respectively.

Despite having lower AGRs, Publisher epidemiologists forecast that the US will have the highest number of prevalent cases of MS by 2023, with 303,343, followed by Canada with 142,199 and Germany with 140,209.

According to Senior Epidemiologist, says: “Regional differences in MS prevalence and incidence could be due to several factors, including the differing diagnostic criteria used, the availability of medical technology, genetic and environmental risk factors, the frequency of comorbidities, and population age and sex structures.”

Although China and India had significantly lower MS incidence rates than the other countries in 2013, their large population sizes are the main factor contributing to their high number of incident cases, according to Publisher.

According to Senior Epidemiologist continues: “With less availability of diagnostic MRI technology in China and India, compared with western countries, case ascertainment in these countries is not as precise. Less accurate case diagnosis can result in diseases, such as neuromyelitis optica, being misclassified as MS, and may have resulted in an overestimation of the latter’s incidence in China and India.”

Low MS prevalence proportions in these countries could also be related to the genetic makeup of these populations, as MS is more commonly diagnosed in Caucasians than individuals of any other race/ethnicity. This is even the case in western countries where MRI technology is widely available.

EpiCast Report: Multiple Sclerosis - Epidemiology Forecast to 2023 report provides an overview of the risk factors and comorbidities of Multiple Sclerosis, and global and historical trends in the 10 major markets (the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India). It includes a 10-year epidemiological forecast of MS prevalent and incident cases segmented by sex and age.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by Publisher’s team of industry experts.

Browse this report: http://mrr.cm/ZfP

Find All Pharma and Healthcare Report at: http://www.marketresearchreports.com/pharma-healthcare

Canada Cardiovascular Prosthetic Devices Market Outlook to 2020 , New Report Launched

"Canada Cardiovascular Prosthetic Devices Market Outlook to 2020", provides key market data on the Canada Cardiovascular Prosthetic Devices market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market categories – Cardiac Valve Repairs and Septal Occluders.

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Cardiovascular Prosthetic Devices market wherever available.

The data in the report is derived from dynamic market forecast models. Publisher uses epidemiology and capital equipment–based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Capital equipment–based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

• Market size for Cardiovascular Prosthetic Devices categories – Cardiac Valve Repairs and Septal Occluders.
• Annualized market revenue (USD million), volume (units) and average selling price ($) data for the market categories. Data is provided from 2005 to 2012 and forecast to 2020.
• 2012 company shares and distribution shares data for the market category.
• Global corporate-level profiles of key companies operating within the Canada Cardiovascular Prosthetic Devices market.
• Key players covered include Medtronic, Inc., Edwards Lifesciences Corporation, St. Jude Medical, Inc. and Sorin Group.

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth in the future.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the market.
• Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.
•  

Spanning over 38 pages, 14 tables, 12 figures, “Canada Cardiovascular Prosthetic Devices Market Outlook to 2020” report covering the Cardiovascular Prosthetic Devices Market, Canada, Overview of Key Companies in Canada, Cardiovascular Prosthetic Devices Market, Cardiovascular Prosthetic Devices Market Pipeline Products, Appendix. The report covered 5 companies - St. Jude Medical, Inc., Edwards Lifesciences Corporation, Medtronic, Inc., W. L. Gore & Associates, Inc., Sorin S.p.A.

Browse this report: http://mrr.cm/Zfm

Find All Medical Devices Report at: http://www.marketresearchreports.com/energy-utilities

Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options, New Report Launched

Thanks to an increasing uptake of branded drugs in Asia-Pacific (APAC), the region’s breast cancer therapeutics market value will climb from $1.5 billion in 2013 to $2.5 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 7.6%, forecasts business intelligence provider Publisher.

According to the company’s latest report*, Japan had the largest market in 2013 with a share of 58%, followed by China and Australia, with respective shares of 21% and 16%. Despite India having the lowest share in 2013, the country will witness the fastest growth over the forecast period, with a CAGR of 13.8%.

According to Senior Analyst, says: “The use of targeted therapies is expected to increase in the APAC markets as patient access to these more expensive agents improves, aided by the entry of a biosimilar version of trastuzumab.”

These targeted therapies will consist of novel and modified Human Epidermal growth factor Receptor (HER-2)-targeting agents, such as Perjeta and antibody drug conjugate Kadcyla, both from Roche, and novel chemotherapeutic agents from Eisai's Halaven. Others, such as Pfizer’s palbociclib and neratinib, and Boehringer Ingelheim’s afatinib, will also contribute.

According to Senior Analyst continues: “The breast cancer pipeline is highly robust with potential drug candidates in various phases of clinical development. With more than 600 active pipeline molecules, the majority of the investigational drug candidates are being evaluated for the treatment of breast cancer in advanced stages, either as first-line or second-line therapies.”

From a total of 612 active progressing pipeline molecules, 42% are in the preclinical stage of development, 16% are in Phase I, 21% are in Phase II and 8% are in Phase III, according to Publisher.

Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options report analyzes treatment usage patterns, market characterization, pipeline analysis, key licensing and co-development deals in the breast cancer therapeutics market in Australia, China, India and Japan.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by Publisher’s team of industry experts.

Know more about this report at: http://mrr.cm/ZNr

Find all Diseases Reports at : http://www.marketresearchreports.com/diseases  

Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies, New Report Launched

Population Growth and Inflation to Drive Market

Publisher has identified and analyzed 10 promising late-stage pipeline drugs (see section 5). However, of these 10, only Telik’s Telcyta has been shown to improve median patient Overall Survival (OS); however, questions raised over the validity of the data mean that the drug is not expected to be approved within the forecast period of 2013–2020. Further Phase III trials of the drug are required, for which Telcyta is currently seeking corporate partners. Most of the late-stage drugs provide no clinical benefit to patients, with the best responses being mild to moderate improvements in Progression-Free Survival (PFS) in comparison with standard-of care treatment. In the projected scenario, those drugs that have been shown to provide an improvement in PFS will be approved in the EU, Canada and Japan. These are Vynfinit, olaparib and Trebananib. This is in line with the most recent drug approvals in these markets: Avastin and Yondelis, which were approved on the basis of improved PFS. However, the expected high cost of these drugs and their minimal clinical benefit, are expected to create a negative opinion of them among healthcare professionals and regulatory bodies in these three geographies, limiting their prescription volumes.

In the US, the improvements in PFS observed with Yondelis and Avastin were not sufficient for either drug to be granted approval in the US. However, despite its refusal, Avastin is approved for other indications within oncology, with evidence that the drug is prescribed off-label for the treatment of Ovarian Cancer (OC) in the US, contributing significantly to the current market (Burger, 2007). The inflation of Avastin, which costs up to $100,000 for a course of treatment, is expected to be a major contributor to market growth in the US and globally. Given the similar lack of OS benefit with current late-stage pipeline drugs, it is unlikely the aforementioned late-stage pipeline drugs will be approved in the US within the forecast period.

Despite the lack of new approvals in this territory the growth of the global market is expected to be driven primarily by growth in the US market. As discussed, no new drugs are expected to be approved in this territory, in which there is a small increase in the prevalence population. Growth is expected to instead be driven by inflation on the cost of therapy, which currently averages $30,000. Inflationary pressure on Avastin, in particular is expected to drive growth. This high inflation rate, not observed across other territories, will result in the North American market becoming increasingly dominant in the global market, within the forecast period.

Lack of Targeted Therapies Being Addressed by Current Developmental Pipeline

There is currently a lack of targeted therapies indicated for the treatment of OC, certainly in comparison with other indications within oncology. Avastin is the only approved targeted therapy and was approved in the EU in 2011 on the basis of improved PFS. The current treatment of OC is dominated by the use of off-patent chemotherapeutic agents: primarily carboplatin, paclitaxel, pegylated liposomal doxorubicin, topotecan and gemcitabine. The current development pipeline appears to be focusing on this lack of targeted therapies, with a wide range of novel targets specific to ovarian tumor cell growth and progression, including growth factors, serine/threonine protein kinases and tumor-associated antigens/genes.

Improvements in Clinical Trial Design Necessary

Recent insights have highlighted that OC is a highly heterogeneous disease with mutations in a range of signaling pathways involved in the initiation and propagation of the disease. Furthermore associated mutations vary among the different histological subtypes and stages of the disease, adding further levels of complexity to the treatment of OC (Wang et al., 2005; Lawrenson et al., 2011). Clinical trials of marketed and current late-stage pipeline drugs have rarely taken this heterogeneity into account, and results across all patient cohorts are usually aggregated, regardless of patients’ disease histology and variations in genetic alterations. The poor results obtained, particularly with pipeline drugs, demonstrate that this ‘‘universal approach’’ is not efficient, and more efforts need to be made to explore the effects of drugs in different disease subtypes. However, it is recognized that further molecular studies are necessary to fully understand the etiology of each disease histotype and make these analyses by subtype fully applicable (Karst and Drapkin, 2010). There is evidence that the genetic and epigenetic characteristics of patients are beginning to be taken into account. Post-hoc analyses of the late-stage pipeline drug olaparib demonstrated that this drug had improved efficacy in patients with Breast Cancer (BRCA) mutation.

Know more about this report at: http://mrr.cm/ZNK

Find all Pharma and Healthcare Reports at : 

http://www.marketresearchreports.com/pharma-healthcare

World Vitamin and Provitamin Market to Grow 2.6% annually from 2014 to 2018, Reveals New Report

According to recently published research conducted by a leading international market research company, Global Research & Data Services, the expansion of the global vitamin and provitamin industry is forecast to reach 2.6% p.a. in the coming years. Between 2007 and 2013 the market increased with an average annual growth of 8.0%. Currently, vitamin E accounts for 37.0% of the global demand while the remaining market share is divided between vitamin C (17.4%), vitamin A (5.2%), vitamin B1 (4.4%), vitamin B6 (4.0%), vitamin B12 (3.8%), vitamin B3 and B5 (3.0%), vitamin B2 (2.7%) and other vitamins and provitamins (22.5%).

China, India, Japan, Singapore, and the United States represent the largest vitamin and provitamin markets while the strongest annual growth is forecast to occur in Slovenia (42.4%), Belgium (22.0%), Netherlands (14.2%), Panama (11.3%), Slovakia (10.9%). 

Based on in-house analysis and an advanced model which takes into consideration the actual market size, trends, forecast market growth, and changes in the market environment, Global Research and Data Services calculates the Market Potential Rates, the predicted market potential of the country in the coming years. The larger the Market Potential Rate, the more potential the market has in the coming years; and conversely, the smaller the rate, the less potential the market is considered to have in the future. Based on these Market Potential Rates, the top 20 highest potential vitamin and provitamin markets in the coming years are: 

The market information is based on new industry data reports recently published by Global Research & Data Services. The reports offer the most up-to-date market data on the actual market situation, trends, and future outlook for vitamins and provitamins in the world and individually for the following countries:

Argentina, Armenia, Australia, Austria, Azerbaijan, Belgium, Bolivia, Bulgaria, Canada, Chile, China, Colombia, Czech Republic, Denmark, Ecuador, Egypt, Estonia, Ethiopia, Finland, France, Georgia, Germany, Ghana, Greece, Hungary, India, Indonesia, Ireland, Italy, Japan, Jordan, Kazakhstan, Latvia, Lebanon, Lithuania, Macedonia, Malaysia, Mexico, Moldova, Morocco, Netherlands, Nigeria, Norway, Oman, Pakistan, Panama, Peru, Philippines, Poland, Portugal, Romania, Russia, Senegal, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sri Lanka, Sweden, Thailand, Turkey, Ukraine, United Kingdom, United States, Uruguay, Vietnam.

The information are extracted from our recently published reports, you can browse country wise reports here: Vitamin and Provitamin Market Reports

The reports include historic market data from 2007 to 2013 and forecasts until 2018 which makes the reports an invaluable resource for industry executives, marketing, sales and product managers, analysts, and other people looking for key industry data in readily accessible and clearly presented tables and graphs.

The latest market data for this research include:

• Overall vitamin and provitamin market size, 2007-2018
• Vitamin and provitamin market size by product segment, 2007-2018
• Growth rates of the overall vitamin and provitamin market and different product segments, 2007-2018
• Shares of different product segments of the overall vitamin and provitamin market, 2007, 2013 and 2018
• Market Potential Rates of the overall vitamin and provitamin market and different product segments

The product segments analyzed in the data reports include:

• Vitamin A
• Vitamin B1
• Vitamin B12
• Vitamin B2
• Vitamin B3 and B5
• Vitamin B6
• Vitamin C
• Vitamin E
• Other vitamins and provitamins

The reports answer the following questions:

• What is the current size of the vitamin and provitamin market in the world and in different countries?
• How is the vitamin and provitamin market divided into different product segments?
• How are the overall market and different product segments growing?
• How is the market predicted to develop in the future?
• What is the market potential compared to other countries?

Know more Pharmaceutical Manufacturing report at: 

http://www.marketresearchreports.com/pharmaceutical-manufacturing